SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-022843
Filing Date
2023-06-29
Accepted
2023-06-29 08:11:30
Documents
15
Period of Report
2023-06-29
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44868
2 ex99-1.htm EX-99.1 24782
3 ex99-1_001.jpg GRAPHIC 2858
  Complete submission text file 0001493152-23-022843.txt   298140

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cing-20230629.xsd EX-101.SCH 4049
5 XBRL DEFINITION FILE cing-20230629_def.xml EX-101.DEF 26635
6 XBRL LABEL FILE cing-20230629_lab.xml EX-101.LAB 36718
7 XBRL PRESENTATION FILE cing-20230629_pre.xml EX-101.PRE 25259
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5274
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

IRS No.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 231054369
SIC: 2834 Pharmaceutical Preparations